FR3020947B1 - Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations - Google Patents

Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations Download PDF

Info

Publication number
FR3020947B1
FR3020947B1 FR1454314A FR1454314A FR3020947B1 FR 3020947 B1 FR3020947 B1 FR 3020947B1 FR 1454314 A FR1454314 A FR 1454314A FR 1454314 A FR1454314 A FR 1454314A FR 3020947 B1 FR3020947 B1 FR 3020947B1
Authority
FR
France
Prior art keywords
protein
preparation
aqueous composition
solubilizing agent
solubilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1454314A
Other languages
English (en)
Other versions
FR3020947A1 (fr
Inventor
Remi Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to FR1454314A priority Critical patent/FR3020947B1/fr
Priority to PCT/EP2015/060732 priority patent/WO2015173377A1/fr
Priority to US14/712,328 priority patent/US20150335751A1/en
Publication of FR3020947A1 publication Critical patent/FR3020947A1/fr
Priority to US15/694,534 priority patent/US10525133B2/en
Application granted granted Critical
Publication of FR3020947B1 publication Critical patent/FR3020947B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
FR1454314A 2014-05-14 2014-05-14 Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations Expired - Fee Related FR3020947B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1454314A FR3020947B1 (fr) 2014-05-14 2014-05-14 Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
PCT/EP2015/060732 WO2015173377A1 (fr) 2014-05-14 2015-05-14 Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US14/712,328 US20150335751A1 (en) 2014-05-14 2015-05-14 Aqeous composition comprising at least one protein and one solubilizing agent, preparation thereof and uses thereof
US15/694,534 US10525133B2 (en) 2014-05-14 2017-09-01 Aqueous composition comprising at least one protein and one solubilizing agent, preparation thereof and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1454314 2014-05-14
FR1454314A FR3020947B1 (fr) 2014-05-14 2014-05-14 Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations

Publications (2)

Publication Number Publication Date
FR3020947A1 FR3020947A1 (fr) 2015-11-20
FR3020947B1 true FR3020947B1 (fr) 2018-08-31

Family

ID=51905196

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1454314A Expired - Fee Related FR3020947B1 (fr) 2014-05-14 2014-05-14 Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations

Country Status (3)

Country Link
US (2) US20150335751A1 (fr)
FR (1) FR3020947B1 (fr)
WO (1) WO2015173377A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
US2847385A (en) 1954-10-07 1958-08-12 Ohio Commw Eng Co Detergent-soil suspending composition containing carboxymethyl dextran
IT1053718B (it) 1973-04-04 1981-10-10 Zambeletti Spa L Metodo per prolungare l azione di farmaci attraverso la formazione di composti mcromolecolari
US4006059A (en) 1974-07-29 1977-02-01 Purdue Research Foundation Hydrophobic noncovalent binding of proteins to support materials
US4011137A (en) 1974-08-26 1977-03-08 Standard Brands Incorporated Process for producing dextrose using mixed immobilized enzymes
US4126628A (en) 1977-03-28 1978-11-21 Canadian Patents And Development Limited Acylation of amino acids
JPS53137911A (en) 1977-05-06 1978-12-01 Showa Denko Kk Preparation of n-(alpha-hydroxyalkanoyl)-peptides
US4438029A (en) 1978-01-19 1984-03-20 Research Corporation Synthetic peptides
AU550068B2 (en) 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
DE3382112D1 (de) * 1982-04-30 1991-02-21 Ajinomoto Kk Pharmazeutische zusammensetzung.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4826818A (en) 1983-10-26 1989-05-02 Kanebo Ltd. Proteinaceous emulsifier, process for preparing same and emulsion type cosmetic compositions containing same
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PL149145B1 (en) 1986-12-17 1990-01-31 The method of obtaining of symmetrical diamides of citric acid
DE10075034I1 (de) 1987-02-25 2001-05-23 Novo Nordisk As Insulinderivate
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
JPH03153653A (ja) 1989-11-10 1991-07-01 Kuraray Co Ltd Ｎ―（１―アルコキシカルボニルスチリル）フマルアミド酸およびその製造方法
US5382574A (en) 1989-12-21 1995-01-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
CA2035248A1 (fr) 1990-02-06 1991-08-07 Shang-Ren Wu Composes de carbamate de vinyle eet compositions detergentes renfermant ce compose
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US5310937A (en) 1991-06-10 1994-05-10 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents and method for the preparation thereof
NZ260933A (en) 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
JPH0782225A (ja) 1993-09-14 1995-03-28 Fuji Photo Film Co Ltd アミノ酸誘導体及びその用途
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JP2002500196A (ja) 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ 安定化させたインスリン組成物
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
US6991798B1 (en) * 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU3841500A (en) 1999-04-22 2000-11-10 Sankyo Company Limited Resin-bearing ketoamides and process for the preparation thereof
CA2421575C (fr) * 2000-09-06 2011-07-12 Emisphere Technologies, Inc. Composes d'acide cyanophenoxycarboxylique et compositions servant a administrer des agents actifs
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
GB0119665D0 (en) 2001-08-10 2001-10-03 Isis Innovation Conjugates
JP4508646B2 (ja) * 2002-01-09 2010-07-21 エミスフェアー・テクノロジーズ・インク ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体
US20060135480A1 (en) 2002-12-03 2006-06-22 Enobia Pharma Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
EP1623979A4 (fr) 2003-02-24 2008-11-26 Japan Science & Tech Agency Complexe de lanthanide fluorescent
US7544656B2 (en) 2003-03-04 2009-06-09 The Technology Development Company, Ltd. Long acting injectable insulin composition and methods of making and using thereof
US20040230167A1 (en) 2003-04-22 2004-11-18 Steiner Ventures Llc Pad for cleaning and hydrating skin
PT103003A (pt) 2003-08-04 2005-02-28 Inst Superior Tecnico Novos inibidores de metalo-enzimas com potencial aplicacao em medicina
CN100372862C (zh) 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
WO2005072803A1 (fr) 2004-01-16 2005-08-11 Biodel, Inc. Dispositif d'administration sublinguale de medicaments
US20080096800A1 (en) 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
JP5022213B2 (ja) 2004-03-12 2012-09-12 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
FR2914305B1 (fr) 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
US20070244467A1 (en) 2005-09-28 2007-10-18 Biodel, Inc., State Of Incorporation Delaware Self-Filling Two Chamber Injectable Device
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2007177182A (ja) 2005-12-28 2007-07-12 Dai Ichi Kogyo Seiyaku Co Ltd 乳化重合用乳化剤、ポリマーエマルションの製造方法及びポリマーエマルション
JP2007177185A (ja) 2005-12-28 2007-07-12 Dai Ichi Kogyo Seiyaku Co Ltd 乳化重合用乳化剤、ポリマーエマルションの製造方法及びポリマーエマルション
IL172896A0 (en) 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US20070191757A1 (en) 2006-02-16 2007-08-16 Biodel Inc. Method and Device for Sublingual Drug Delivery Using Iontophoresis
AU2007235821A1 (en) 2006-04-07 2007-10-18 Adocia Bifunctionalized polysaccharides
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US20120041079A1 (en) 2006-09-26 2012-02-16 Adocia Dextran functionalized by hydrophobic amino acids
EP2081565A2 (fr) * 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Nouveaux agents chimiothérapeutiques contre l'inflammation et le cancer
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008124522A2 (fr) 2007-04-04 2008-10-16 Biodel, Inc. Formulations contenant de l'amyline
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
FR2927900B1 (fr) 2008-02-27 2010-09-17 Clariant Specialty Fine Chem Procede de preparation d'alpha-aminoacetals optiquement actifs.
EP2288370A1 (fr) 2008-04-14 2011-03-02 Adocia Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation e un support organique
JP4672815B2 (ja) 2008-05-07 2011-04-20 東洋紡績株式会社 Ｌ−サクシニルアミノアシラーゼ、およびこれを用いたｌ−アミノ酸の製造方法
FR2934999B1 (fr) 2008-08-13 2011-07-29 Adocia Polysaccharides fonctionnalises par des derives du tryptophane
WO2010028055A1 (fr) 2008-09-02 2010-03-11 Biodel, Inc. Insuline dotée d’un profil de libération basal
EP2349338A2 (fr) 2008-09-26 2011-08-03 Adocia Complexe constitue d'un polysaccharide et d'une hpb
FR2940802A1 (fr) 2008-10-10 2010-07-09 Adocia Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide.
WO2010037180A1 (fr) 2008-10-03 2010-04-08 Glycan Biosciences Pty Ltd Conjugués d’oligosaccharides anioniques
FR2936800B1 (fr) 2008-10-06 2010-12-31 Adocia Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe
JP5542687B2 (ja) 2008-11-05 2014-07-09 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
FR2948573B1 (fr) 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
JP5232247B2 (ja) 2008-12-11 2013-07-10 東洋紡株式会社 Ｌ−サクシニルアミノアシラーゼ、およびこれを用いたｌ−アミノ酸の製造方法
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
FR2980796B1 (fr) 2011-09-30 2014-07-04 Adocia Oligosaccharides fonctionnalises
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
CN101920019B (zh) 2009-06-10 2012-06-06 浙江中医药大学 亲水性聚合物-葛根素特异性缀合的非溶血性缀合物
JP5669834B2 (ja) 2009-06-26 2015-02-18 ノボ・ノルデイスク・エー／エス インスリン、ニコチンアミド及びアミノ酸を含む製剤
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
FR2958647B1 (fr) 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
WO2011098962A2 (fr) 2010-02-09 2011-08-18 Adocia Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent
US8476238B2 (en) * 2010-06-29 2013-07-02 Mycomagic Biotechnology Co., Ltd. Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
JP5806664B2 (ja) 2010-06-30 2015-11-10 積水メディカル株式会社 Ｄ−サクシニラーゼ、およびこれを用いたｄ−アミノ酸の製造方法
CA2805031A1 (fr) 2010-07-07 2012-01-12 Biodel, Inc. Compositions et procedes pour la modulation de la pharmacocinetique et de la pharmacodynamie de l'insuline
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
JP5903298B2 (ja) 2011-03-14 2016-04-13 東洋紡株式会社 Ｎ−サクシニル−ｄｌ−アミノ酸に対する向上されたｄ体選択性を有する改変型ｄ−サクシニラーゼ
US20120295833A1 (en) 2011-05-10 2012-11-22 Adocia Polysaccharides having an adjustable degree of functionalization
EP2828297A1 (fr) 2011-05-10 2015-01-28 Adocia Oligosaccharides fonctionnalisés
EP2711077A4 (fr) 2011-05-18 2016-07-06 Mitsubishi Gas Chemical Co Absorbeur d'oxygène
EP2741765B9 (fr) 2011-08-10 2016-09-28 Adocia Solution injectable d'au moins une insuline basale
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013064787A1 (fr) 2011-11-02 2013-05-10 Adocia Formulation à action rapide d'insuline comprenant un oligosaccharide
KR102205512B1 (ko) 2012-11-13 2021-01-20 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
JP2015010075A (ja) 2013-07-01 2015-01-19 学校法人神戸学院 γ−グルタミルシクロトランスフェラーゼ阻害剤
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations

Also Published As

Publication number Publication date
US20180214556A1 (en) 2018-08-02
WO2015173377A1 (fr) 2015-11-19
US10525133B2 (en) 2020-01-07
FR3020947A1 (fr) 2015-11-20
US20150335751A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
DK3559022T3 (da) Virulenssvækket bakteriebaseret proteinlevering
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
BR112016018521A2 (pt) composição, e, kit.
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
DK2986304T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DE112016004087A5 (de) Manschette, Teesiebsystem und System
DK3288988T3 (da) Vandige dispersioner
MA44489A (fr) Pyrimidines et variants de celles-ci, et leurs utilisations
DK3319643T3 (da) HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler
MA47019A (fr) Agents, utilisations et procédés
TR201901228T4 (tr) Vortioksetin piroglutamat.
MA46901A (fr) Agents psychotropes et leurs utilisations
BR112016026143A2 (pt) os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico.
MA41850A (fr) Nouvelles utilisations pharmaceutiques
MX2017003615A (es) Sonda de medicion que comprende un elemento sensible.
FR3040300B1 (fr) Composition comprenant au moins un tensioactif anionique, au moins un tensioactif non ionique, au moins un tensioactif amphotere, au moins un polymere cationique et au moins un polymere amphotere
FR3024733B1 (fr) Agent epaississant pour systemes aqueux, formulations le contenant et utilisations.
BR112016021231A2 (pt) derivados de hexose, preparação e uso destes.
FR3020947B1 (fr) Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FI20145289A (fi) Menetelmä polysakkaridien kationoimiseksi, eutektiset seokset ja niiden käyttö polysakkaridien kationoimiseen

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20151120

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20220105